For advanced colorectal carcinoma, two new drugs, raltitrexed (TOM) and oxaliplatin (l-OHP), have recently shown interesting results. Preclinical and clinical studies because of its favorable toxicity profile, high response rate and convenient schedule of administration, can be administered successfully in this disease. In our phase II study, 37 non pre-treated patiens with metastatic colorectal carcinoma were treated with YOM (3mg/m2) and l-OHP (130mg7m2) every 3 weeks. In total 222 cycles were administered: all patiens received at least 2 cycles (median 6 range 2-8). There were 2 complete and 14 partial response for an overall response rate of 43% (95% CI 27-69%). The median time of response was 2.5 months (range 2-4) and median duration was 10.3 months (range 5-18), patients with symptomatic colorectal cancer were classified as clinical benefit responders for at least 4 weeks during the study period. Treatment was well tolerated, and both acute, essentially hematologic, and cumulable hepatic and neurologic toxicity were menageable and reversible. Response rate and toxic effect observed during study warrant additional studies comparing this TOM-l-OHP regimen with CPT-11 capecitabile-containing regimens in metastatic colorectal caricinoma

Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial / Neri B;Doni L;Fulignati C;Perfetto F;Turrini M;Andreoli F;Pantalone D;Pernice LM;Taruffi F;Martini V;Poma A;Valeri A;Bacci G;Sancez L;Moretti R. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - STAMPA. - 13:(2002), pp. 719-724. [10.1097/00001813-2002208000-00006]

Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial.

NERI, BRUNO;DONI, LORIANA;FULIGNATI, CHIARA;PERFETTO, FEDERICO;ANDREOLI, FRANCESCO;PANTALONE, DESIRE';PERNICE, LUIGI MARIA;TARUFFI, FRANCESCO;
2002

Abstract

For advanced colorectal carcinoma, two new drugs, raltitrexed (TOM) and oxaliplatin (l-OHP), have recently shown interesting results. Preclinical and clinical studies because of its favorable toxicity profile, high response rate and convenient schedule of administration, can be administered successfully in this disease. In our phase II study, 37 non pre-treated patiens with metastatic colorectal carcinoma were treated with YOM (3mg/m2) and l-OHP (130mg7m2) every 3 weeks. In total 222 cycles were administered: all patiens received at least 2 cycles (median 6 range 2-8). There were 2 complete and 14 partial response for an overall response rate of 43% (95% CI 27-69%). The median time of response was 2.5 months (range 2-4) and median duration was 10.3 months (range 5-18), patients with symptomatic colorectal cancer were classified as clinical benefit responders for at least 4 weeks during the study period. Treatment was well tolerated, and both acute, essentially hematologic, and cumulable hepatic and neurologic toxicity were menageable and reversible. Response rate and toxic effect observed during study warrant additional studies comparing this TOM-l-OHP regimen with CPT-11 capecitabile-containing regimens in metastatic colorectal caricinoma
2002
13
719
724
Goal 3: Good health and well-being
Neri B;Doni L;Fulignati C;Perfetto F;Turrini M;Andreoli F;Pantalone D;Pernice LM;Taruffi F;Martini V;Poma A;Valeri A;Bacci G;Sancez L;Moretti R...espandi
File in questo prodotto:
File Dimensione Formato  
Raltitrexed therapy.pdf

Accesso chiuso

Descrizione: confronto tra protocolli di trattamento chemioterapico per il cancro metastatico del colonretto
Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 11.09 MB
Formato Adobe PDF
11.09 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/680172
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 20
social impact